DR. REDDY S LABORATORIES (DRREDDY)

NSE: ₹1,267.50
BSE: ₹1,267.05
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release - Launch of Bosutinib Tablets 400mg.

2026-06-13 13:01:07
2026-06-12 22:35:30
2026-06-05 15:35:02
2026-06-03 12:05:58
2026-06-01 15:37:56
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Limited has informed the Exchange that the Annual Report in Form 20F for the fiscal year ended March 31, 2026 has been filed with United States Securities and Exchange Commission

2026-05-30 13:03:47
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance certificate for the year ended March 31, 2026

2026-05-28 16:38:13
Announcement under Regulation 30 (LODR)-Press Release / Media Release

Disclosure under Regulation 30 of SEBI (LODR) 2015, regarding Press release viz. "Dr. Reddy's Laboratories to Ring the Closing Bell at New York Stock Exchange."

2026-05-28 15:29:37
2026-05-27 21:38:38

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 5,437.30 4,838.70 4,103.00 5,104.80 5,841.20 6,696.30 5,015.00 5,562.90 7,809.50 4,618.60 4,282.70 3,822.00
YOY Revenue Growth % 49.76% -0.85% 5.27% 12.09% 7.43% 38.39% 22.23% 8.97% 33.7% -31.03% -14.6% -31.29%
Other Income 233.60 223.10 227.60 212.70 217.80 207.60 235.40 414.40 398.30 364.20 360.30 567.20
Total Income 5,670.90 5,061.80 4,330.60 5,317.50 6,059.00 6,903.90 5,250.40 5,977.30 8,207.80 4,982.80 4,643.00 4,389.20
Total Expenses + 3,451.30 3,461.20 3,698.70 3,978.30 4,145.10 4,263.10 4,131.00 4,415.50 4,271.50 4,466.50 4,538.80 4,694.70
Cost of Materials Consumed 813.90 751.20 818.70 907.70 911.10 934.30 1,011.70 942.60 1,135.50 1,009.00 1,066.80 1,121.20
Employee Benefit Expense 740.20 783.70 782.30 779.50 855.90 840.10 794.40 797.10 887.30 867.90 960.20 834.50
Other Expenses 1,287.60 1,280.90 1,353.90 1,544.70 1,507.00 1,636.80 1,545.10 1,763.30 1,498.80 1,539.90 1,518.40 1,771.00
Operating Profit 1,986.00 1,377.50 404.30 1,126.50 1,696.10 2,433.20 884.00 1,147.40 3,538.00 152.10 -256.10 -872.70
OPM % 36.5% 28.5% 9.9% 22.1% 29% 36.3% 17.6% 20.6% 45.3% 3.3% -6% -22.8%
Profit Before Tax + 2,219.60 1,600.60 631.90 1,339.20 1,913.90 2,640.80 1,119.40 1,561.80 3,936.30 516.30 104.20 -305.50
Tax Expense 580.20 408.00 156.70 304.40 496.70 758.70 270.00 361.10 975.10 129.00 13.60 -86.10
Tax % 26.1% 25.5% 24.8% 22.7% 26% 28.7% 24.1% 23.1% 24.8% 25% 13.1% -
Profit After Tax 1,639.40 1,192.60 475.20 1,034.80 1,417.20 1,882.10 849.40 1,200.70 2,961.20 387.30 90.60 -219.40
EPS (Basic) 98.66 71.68 28.55 62.14 85.10 22.60 10.20 14.41 35.59 4.65 1.09 -2.63

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 20,532.80 23,115.40 19,483.80 16,962.50 14,405.20 13,349.10 11,850.40
YOY Revenue Growth % -11.17% 18.64% 14.86% 17.75% 7.91% 12.65% -
Other Income 1,689.60 1,003.40 862.30 591.30 482.00 801.10 743.20
Total Income 22,222.40 24,118.80 20,346.10 17,553.80 14,887.20 14,150.20 12,593.60
Total Expenses + 17,971.10 16,882.90 14,554.80 13,687.80 12,663.40 11,094.00 7,963.50
Cost of Materials Consumed 4,332.50 3,799.70 3,291.50 3,161.40 3,378.40 3,266.30 2,556.50
Employee Benefit Expense 3,549.90 3,287.50 3,085.70 2,832.60 2,434.60 2,270.10 2,030.20
Other Expenses 6,327.70 6,380.40 5,432.40 4,844.90 4,330.60 3,819.20 3,376.80
Operating Profit 2,561.70 6,232.50 4,929.00 3,274.70 1,741.80 2,255.10 3,886.90
OPM % 12.5% 27% 25.3% 19.3% 12.1% 16.9% 32.8%
Profit Before Exceptional 4,251.30 7,235.90 5,791.30 3,866.00 2,223.80 3,056.20 2,775.80
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 4,251.30 7,235.90 5,791.30 3,866.00 2,223.80 3,056.20 2,775.80
Tax Expense 1,031.60 1,886.50 1,449.30 1,253.20 600.60 869.80 -161.90
Tax % 24.3% 26.1% 25% 32.4% 27% 28.5% -5.8%
Profit After Tax 3,219.70 5,349.40 4,342.00 2,612.80 1,623.20 2,186.40 2,937.70
EPS (Basic) 38.68 64.22 260.95 157.37 97.85 131.84 177.23

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 25,078.90 21,787.90 12,543.40 11,331.90 10,700.50 10,470.30 0.00
Property, Plant & Equipment 7,752.70 5,865.40 5,109.40 4,737.90 4,024.00 3,579.20 0.00
Capital Work in Progress 1,369.10 2,156.40 1,171.90 899.10 1,186.40 877.10 0.00
Non-Current Investments 12,361.30 10,310.50 3,202.70 3,142.20 3,024.30 3,392.20 0.00
Goodwill 85.30 85.30 85.30 85.30 85.30 85.30 0.00
Other Intangible Assets 2,892.10 2,281.70 2,394.40 2,383.50 2,041.20 2,179.80 0.00
Current Assets + 18,523.20 16,503.00 17,815.90 14,042.90 13,792.50 11,159.30 0.00
Inventories 4,955.60 4,575.80 4,018.90 3,043.00 3,347.80 2,819.70 0.00
Trade Receivables 4,118.60 5,959.00 4,623.90 4,288.90 4,945.40 4,080.00 0.00
Cash and Cash Equivalents 337.50 319.70 201.40 112.30 1,159.50 1,306.30 0.00
Current Investments 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 0.00
LIABILITIES & EQUITY
Total Equity 31,365.60 28,856.60 24,240.80 20,474.20 18,336.20 16,983.70 0.00
Equity Share Capital 83.50 83.40 83.40 83.30 83.20 83.20 0.00
Other Equity 31,282.10 28,773.20 24,157.40 20,390.90 18,253.00 16,900.50 0.00
Non-Current Liabilities 1,094.00 782.50 580.40 460.90 114.30 85.60 0.00
Current Liabilities 11,142.50 8,651.80 5,538.10 4,439.70 6,045.10 4,560.30 0.00
Total Liabilities 12,236.50 9,434.30 6,118.50 4,900.60 6,159.40 4,645.90 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities 4,660.50 4,225.00 3,449.70 5,052.80 1,338.70 0.00 0.00
Cash from Investing Activities -5,784.70 -5,697.60 -3,430.30 -3,447.60 -2,038.00 0.00 0.00
Cash from Financing Activities 1,116.80 1,590.70 68.10 -2,696.90 505.50 0.00 0.00
Net Increase/Decrease in Cash 17.80 118.30 89.10 -1,047.20 -145.90 0.00 0.00